uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QURE uniQure NV

Trading 11-04 13:32:21 EST

22.86

-1.01

-4.25%

High24.22	Low21.51	Vol1.51M
Open24.10	D1 Closing23.87	Amplitude11.33%
Mkt Cap1.59B	Tradable Cap1.31B	Total Shares69.37M
T/O34.08M	T/O Rate2.63%	Tradable Shares57.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QURE","market":"US","secType":"STK","nameCN":"uniQure NV","latestPrice":22.855,"timestamp":1793817140358,"preClose":23.87,"halted":0,"volume":1510373,"delay":0,"changeRate":-0.042521994134897385,"floatShares":57525100,"shares":69366400,"eps":-4.039896,"marketStatus":"Trading","change":-1.015,"latestTime":"11-04 13:32:21 EST","open":24.1,"high":24.215,"low":21.51,"amount":34078585.268698,"amplitude":0.113322,"askPrice":22.98,"askSize":32,"bidPrice":22.72,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-4.039896,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793826000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1391576400000,"exchange":"NASDAQ","adjPreClose":23.87,"preHourTrading":{"tag":"盘前","latestPrice":24.12,"preClose":23.87,"latestTime":"09:29 EST","volume":20051,"amount":466069.975526,"timestamp":1793802599999,"change":0.25,"changeRate":0.010473,"amplitude":0.100545},"postHourTrading":{"tag":"盘后","latestPrice":23.1,"preClose":23.87,"latestTime":"19:30 EST","volume":26574,"amount":631563.176,"timestamp":1793752204717,"change":-0.77,"changeRate":-0.032258,"amplitude":0.036447},"volumeRatio":0.926366,"impliedVol":0.8527,"impliedVolPercentile":0.0598},"requestUrl":"/m/hq/s/QURE","defaultTab":"news","newsList":[{"id":"2680050649","title":"uniQure N.V. Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2680050649","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680050649?lang=en_us&edition=fundamental","pubTime":"2026-11-04 22:31","pubTimestamp":1793802703,"startTime":"0","endTime":"0","summary":"uniQure N.V. reports results for the quarter ended September 30 - Earnings SummaryuniQure N.V.QURE.OQreported a quarterly adjusted loss of 88 cents per share for the quarter ended September 30, higher","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL5N46L24O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","BK4139","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680905099","title":"UniQure Q3 Loss Narrows, Revenue Increases","url":"https://stock-news.laohu8.com/highlight/detail?id=2680905099","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680905099?lang=en_us&edition=fundamental","pubTime":"2026-11-04 22:24","pubTimestamp":1793802295,"startTime":"0","endTime":"0","summary":"UniQure  reported a Q3 loss Wednesday of $0.88 per diluted share, narrower than a loss of $1.38 a year earlier.Analysts polled by FactSet expected a loss of $0.92.Revenue for the quarter ended Sept. 30 was $5.2 million, up from $3.7 million a year earlier.Analysts expected $6.2 million.The company said it expects $768.4 million in cash, cash equivalents and investment securities as of Sept. 30 to fund operations into 2030.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU0109394709.USD","QURE","LU0889565916.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680561550","title":"Ocugen Q3 Revenue Beats Expectations, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2680561550","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680561550?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:25","pubTimestamp":1793795138,"startTime":"0","endTime":"0","summary":"Ocugen Q3 revenue beats expectations, net loss narrowsOverviewUS gene therapy developer's Q3 revenue rose and beat analyst expectationsNet loss per share for Q3 narrowed to $0.01 from $0.07 last yearC","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","ARKG","LU0889565916.HKD","BK4588","LU1861559042.SGD","LU0320765992.SGD","LU1861558580.USD","QURE","BK4556","LU0109394709.USD","BK4563","BK4139","CRSP","OCGN","BK4568","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680699056","title":"Netherlands' uniQure Q3 Revenue Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2680699056","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680699056?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:22","pubTimestamp":1793794968,"startTime":"0","endTime":"0","summary":"Netherlands' uniQure Q3 revenue misses estimatesOverviewNetherlands gene therapy firm's Q3 revenue rose yr/yr but missed analyst expectationsQ3 net loss narrowed compared to prior-year periodCompany's","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0MY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","IE00B19Z9Z06.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","LU0079474960.USD","BK4588","BBH","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE00B19Z9P08.USD","IE0009355771.USD","IE00B19Z3B42.SGD","LU1585245621.USD","BK4566","LU1093756325.SGD","BMRN","IBBQ","IDNA","GNMX","LU0109394709.USD","LU0320765992.SGD","LU0058720904.USD","LU2462157665.USD","LU0823416689.USD","LU0889565916.HKD","LU2456880835.USD","SG9999001176.USD","LU0234570918.USD","PBE","IE00BJJMRZ35.SGD","TBXU","LU1674673428.USD","QURE","LU1035775433.USD","LU1430594728.SGD","BIB","LU1674673691.USD","VRTX","IE0002141913.USD","BK4532","IE00B894F039.SGD","BK4567","IBB","SNDX","LU1069344957.HKD","LU2417539215.USD","BK4533","LU2236285917.USD","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680056977","title":"Earnings Flash (QURE) UniQure Posts Q3 Loss of $0.88 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2680056977","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680056977?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:22","pubTimestamp":1793794940,"startTime":"0","endTime":"0","summary":"Earnings Flash (QURE) UniQure Posts Q3 Loss of $0.88 a Share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680056386","title":"Switzerland's MoonLake Q3 Net Loss Widens as R&D Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2680056386","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680056386?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:18","pubTimestamp":1793794714,"startTime":"0","endTime":"0","summary":"Switzerland's MoonLake Q3 net loss widens as R&D costs riseOverviewSwitzerland biotech posted Q3 net loss as R&D expenses rose on milestone license feesCompany submitted Biologics License Application ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0M4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4585","LU1861559042.SGD","LU0889565916.HKD","BK4139","ARKG","MLTX","CRSP","QURE","BK4611","LU0320765992.SGD","BK4588","LU0109394709.USD","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680055097","title":"uniQure Q3 EPS $(0.88) Beats $(0.92) Estimate, Sales $5.200M Miss $6.178M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2680055097","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680055097?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:15","pubTimestamp":1793794547,"startTime":"0","endTime":"0","summary":"uniQure (NASDAQ:QURE) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(0.92) by 4.35 percent. This is a 36.23 percent increase over losses of $(1.38) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/62859496/uniqure-q3-eps-0-88-beats-0-92-estimate-sales-5-200m-miss-6-178m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680522260","title":"uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2680522260","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680522260?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:05","pubTimestamp":1793793900,"startTime":"0","endTime":"0","summary":"~ FDA granted priority review of BLA forifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ ~ Aligned with FDA on key elements of confirmatory study","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/04/3395189/0/en/uniqure-announces-third-quarter-2026-financial-results-and-provides-company-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","MAA","BLA.AU","BK4211","IAT","LU0109394709.USD","LU0889565916.HKD","BK4139","LU2237438978.USD","LU0320765992.SGD","FTXO","TFC","SPRE","QURE","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680072506","title":"Beam Therapeutics Posts Wider than Expected Q3 Net Loss as Revenue Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2680072506","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680072506?lang=en_us&edition=fundamental","pubTime":"2026-11-03 20:17","pubTimestamp":1793708253,"startTime":"0","endTime":"0","summary":"Beam Therapeutics posts wider than expected Q3 net loss as revenue dropsOverviewUS biotechnology firm reported wider-than-expected Q3 operating loss and net lossLicense and collaboration revenue decli","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nL2N46K0HR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARKG","BK4585","BK4611","TVTX","BK4588","LU0109394709.USD","LU1861558580.USD","BK4505","BK4535","LU0320765992.SGD","BEAM","LU0889565916.HKD","CRSP","LU1861559042.SGD","QURE","BK4556","LFSC","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680472546","title":"Arvinas Q3 Revenue Drops Sharply on Lower Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2680472546","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680472546?lang=en_us&edition=fundamental","pubTime":"2026-11-03 20:11","pubTimestamp":1793707884,"startTime":"0","endTime":"0","summary":"Arvinas Q3 revenue drops sharply on lower milestone paymentsOverviewUS biotech firm's Q3 revenue fell sharply yr/yr due to lower milestone and collaboration paymentsCompany posted a wider net loss in ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nL2N46K0I5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","QURE","BK4588","LU0154245756.USD","LU2065171311.SGD","BK4139","LU2065171402.SGD","LU1861558580.USD","LU0154245673.USD","BK4556","ARKG","LU2324357040.USD","BK4585","CRSP","NBIX","LU1861559042.SGD","BK4611","LU2065170008.USD","LU0320765992.SGD","LU0823416689.USD","LU0109394709.USD","ARVN","BK4007","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680598714","title":"Netherlands' Philips Slightly Misses Q3 Revenue Estimates, Maintains 2026 Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2680598714","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680598714?lang=en_us&edition=fundamental","pubTime":"2026-11-03 14:09","pubTimestamp":1793686181,"startTime":"0","endTime":"0","summary":"Netherlands' Philips slightly misses Q3 revenue estimates, maintains 2026 forecastOverviewNetherlands health technology firm's Q3 revenue rose 3%, slightly missing analyst expectationsAdjusted EBITA m","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nL2N46K06B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","BK4139","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680980617","title":"Travere Q3 Product Sales Nearly Double on Filspari Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2680980617","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680980617?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:12","pubTimestamp":1793653949,"startTime":"0","endTime":"0","summary":"Travere Q3 product sales nearly double on FILSPARI growthOverviewU.S. biopharma firm's Q3 product sales rose 95% yr/yr, driven by FILSPARI growthCompany posted Q3 net loss, reversing profit from prior","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nL2N46J0YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245673.USD","TVTX","LFSC","LU0511384066.AUD","LU2324357040.USD","QURE","LU0689626769.HKD","LU0472753341.HKD","CMI","BK4583","LU0289961442.SGD","BK4149","LU0109394709.USD","LU0203345920.USD","IE000M9KFDE8.USD","BK4567","BK4585","LU2463526074.USD","MADE","LU0124676726.USD","LU0289739343.SGD","INO","LU0057025933.USD","BK4139","BK4588","LU0320765992.SGD","BK4568","LU0889565916.HKD","BK4533","LU0154245756.USD","LU0203347892.USD","LU0069063385.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680982027","title":"BioMarin Q3 Revenue Rises on Amicus Acquisition, Adjusted EPS Beats","url":"https://stock-news.laohu8.com/highlight/detail?id=2680982027","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680982027?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:10","pubTimestamp":1793653834,"startTime":"0","endTime":"0","summary":"BioMarin Q3 revenue rises on Amicus acquisition, adjusted EPS beatsOverviewRare disease biotech's Q3 revenue rose 32% yr/yr, meeting analyst expectationsAdjusted EPS for Q3 beat analyst estimatesGrowt","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nL2N46J0Z0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BMRN","IE0002270589.USD","KRYS","LU0109394709.USD","BK4139","PSCH","BK4566","BK4007","LU0320765992.SGD","IE00B7SZLL34.SGD","BK4585","HELX","BK4505","PTH","AXSM","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680288798","title":"Switzerland's Crispr Therapeutics Q3 Casgevy Revenue Jumps 30% Sequentially","url":"https://stock-news.laohu8.com/highlight/detail?id=2680288798","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680288798?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:09","pubTimestamp":1793653771,"startTime":"0","endTime":"0","summary":"Switzerland's CRISPR Therapeutics Q3 CASGEVY revenue jumps 30% sequentiallyOverviewSwitzerland-based gene-editing firm's Q3 CASGEVY revenue rose 30% sequentially, nearly six times yr/yrCompany expande","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nL2N46J0YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4585","LU0109394709.USD","AXSM","BK4007","QURE","LU2324357040.USD","PTH","LU0889565916.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680798419","title":"Syndax Pharmaceuticals Q3 Revenue Rises 82% on Cancer Drug Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2680798419","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680798419?lang=en_us&edition=fundamental","pubTime":"2026-11-03 05:08","pubTimestamp":1793653697,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Q3 revenue rises 82% on cancer drug salesOverviewUS biopharma firm's Q3 revenue rose 82% yr/yr, driven by Revuforj and Niktimvo salesQ3 net loss narrowed yr/yr but missed analys","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nL2N46J0YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739343.SGD","LU0289961442.SGD","BK4567","LU0069063385.USD","BK4149","LU0057025933.USD","BK4505","LU0472753341.HKD","LU0203345920.USD","BK4585","QURE","LU2324357040.USD","LU0109394709.USD","AXSM","IE000M9KFDE8.USD","BK4139","LU0203347892.USD","PTH","SNDX","LU0154245673.USD","LU0689626769.HKD","LU0154245756.USD","LU0124676726.USD","LU0320765992.SGD","MADE","BK4588","LU0889565916.HKD","BK4533","LU0511384066.AUD","LU2463526074.USD","BK4007","CMI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680675248","title":"uniQure announces FDA acceptance, priority review for ifezuntirgene inilparvovec","url":"https://stock-news.laohu8.com/highlight/detail?id=2680675248","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680675248?lang=en_us&edition=fundamental","pubTime":"2026-11-02 20:39","pubTimestamp":1793623154,"startTime":"0","endTime":"0","summary":"uniQure (QURE) announced the FDA has accepted for review the biologics license application, or BLA, for ifezuntirgene inilparvovec, an investigatio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-announces-fda-acceptance-priority-review-for-ifezuntirgene-inilparvovec-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-announces-fda-acceptance-priority-review-for-ifezuntirgene-inilparvovec-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","LU0109394709.USD","BK4588","QURE","LABU","LU0889565916.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680880754","title":"FDA Grants Priority Review to uniQure's Huntington's Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2680880754","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680880754?lang=en_us&edition=fundamental","pubTime":"2026-11-02 20:06","pubTimestamp":1793621190,"startTime":"0","endTime":"0","summary":"FDA grants priority review to uniQure's Huntington's gene therapyFDA accepted uniQure's approval application for Huntington's disease gene therapy ifezuntirgene inilparvovec, granting priority review.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDL505Pz7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","LU2095319765.USD","LU0109394709.USD","NDAQ","LU0314104364.USD","LU0889565916.HKD","BK4585","LU2210150020.SGD","QURE","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU0320765992.SGD","IE00BQXX3F31.USD","BCDF","IE00BQXX3D17.EUR","SG9999014021.USD","BK4588","SG9999014039.USD","BK4139","LU2210149790.SGD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679265013","title":"uniQure (QURE) Faces AMT 130 Scrutiny, Is It Still 60% Undervalued?","url":"https://stock-news.laohu8.com/highlight/detail?id=2679265013","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679265013?lang=en_us&edition=fundamental","pubTime":"2026-10-30 13:37","pubTimestamp":1793338656,"startTime":"0","endTime":"0","summary":"uniQure (NasdaqGS:QURE) is under closer scrutiny after fresh questions around AMT-130 trial data prompted a securities investigation, putting the durability of its gene therapies and current valuation against book value under the spotlight for investors.\nMomentum around uniQure has swung sharply this year, with a 1-week share price return of 9.5% and a 30-day gain of 3.2% contrasting with a 90-day share price decline of 42%. The 1-year total shareholder return is down 62.7%, despite a very...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-faces-amt-130-scrutiny-is-it-still-60-undervalu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-faces-amt-130-scrutiny-is-it-still-60-undervalu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","LU0109394709.USD","REAI","HELS","IDGT","URE","BK4139","LU0889565916.HKD","BK4581","BYRE","BK4534","DTCR","WTRE","BK4554","SRVR","PSR","BK4084","BK4219","LU0320765992.SGD","FREL","TRUR","CRED","CDIG","DFGR","AMT","XLRE","VNQ","ICF","QURE","DTRE","AVRE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679647358","title":"H.C. Wainwright Sticks to Their Buy Rating for uniQure (QURE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2679647358","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679647358?lang=en_us&edition=fundamental","pubTime":"2026-10-29 16:35","pubTimestamp":1793262932,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on uniQure, with a price target of $80.00. The compan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675553569","title":"UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2675553569","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675553569?lang=en_us&edition=fundamental","pubTime":"2026-10-15 22:51","pubTimestamp":1792075899,"startTime":"0","endTime":"0","summary":"uniQure N.V (QURE) has an average rating of buy and mean price target of $59.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","QURE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uniqure.com","stockEarnings":[{"period":"1week","weight":-0.0169},{"period":"1month","weight":0.0175},{"period":"3month","weight":-0.4604},{"period":"6month","weight":-0.0116},{"period":"1year","weight":-0.3039},{"period":"ytd","weight":-0.0025}],"compareEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.0199},{"period":"3month","weight":-0.0201},{"period":"6month","weight":0.0311},{"period":"1year","weight":0.1039},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.009035},{"month":2,"riseRate":0.5,"avgChangeRate":0.032875},{"month":3,"riseRate":0.307692,"avgChangeRate":-0.046417},{"month":4,"riseRate":0.461538,"avgChangeRate":0.033828},{"month":5,"riseRate":0.692308,"avgChangeRate":0.072742},{"month":6,"riseRate":0.461538,"avgChangeRate":0.038554},{"month":7,"riseRate":0.230769,"avgChangeRate":0.026458},{"month":8,"riseRate":0.538462,"avgChangeRate":0.014427},{"month":9,"riseRate":0.230769,"avgChangeRate":0.07452},{"month":10,"riseRate":0.538462,"avgChangeRate":0.057882},{"month":11,"riseRate":0.692308,"avgChangeRate":0.053887},{"month":12,"riseRate":0.25,"avgChangeRate":0.125134}],"exchange":"NASDAQ","name":"uniQure NV","nameEN":"uniQure NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"uniQure NV,QURE,uniQure NV股票,uniQure NV股票老虎,uniQure NV股票老虎国际,uniQure NV行情,uniQure NV股票行情,uniQure NV股价,uniQure NV股市,uniQure NV股票价格,uniQure NV股票交易,uniQure NV股票购买,uniQure NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction